Tags

Type your tag names separated by a space and hit enter

Prophylaxis of venous thromboembolism disease in patients with cancer.
Rev Clin Esp. 2020 Jun 09 [Online ahead of print]RC

Abstract

Thrombotic risk should always be assessed in the various clinical scenarios of patients with cancer. Thromboprophylaxis with low-molecular-weight heparin is recommended above other anticoagulants for most patients with cancer who are hospitalised. However, the safety of primary thromboprophylaxis in this context is unknown; however, thromboprophylaxis can be completed with mechanical methods. Thromboprophylaxis in outpatients who are treated with chemotherapy is not indicated, except for outpatients who have other factors that determine a high thrombotic risk. In these cases, prophylaxis such as apixaban, rivaroxaban and low-molecular-weight heparin may be employed, provided there are no significant risk factors for bleeding or drug interactions. In patients undergoing oncologic surgery, thromboprophylaxis should be started before the surgery, continuing for at least 7 to 10 days and, in cases of major surgery, even up to 4 weeks. Drug prophylaxis is not routinely recommended to prevent upper extremity thrombosis in patients who carry central venous catheters.

Authors+Show Affiliations

Departamento de Medicina Interna, Hospital General Universitario de Ciudad Real, Facultad de Medicina, Ciudad Real, España. Electronic address: jportillos@outlook.com.

Pub Type(s)

Journal Article
Review

Language

eng spa

PubMed ID

32532465

Citation

Portillo Sánchez, J. "Prophylaxis of Venous Thromboembolism Disease in Patients With Cancer." Revista Clinica Espanola, 2020.
Portillo Sánchez J. Prophylaxis of venous thromboembolism disease in patients with cancer. Rev Clin Esp. 2020.
Portillo Sánchez, J. (2020). Prophylaxis of venous thromboembolism disease in patients with cancer. Revista Clinica Espanola. https://doi.org/10.1016/j.rce.2020.04.018
Portillo Sánchez J. Prophylaxis of Venous Thromboembolism Disease in Patients With Cancer. Rev Clin Esp. 2020 Jun 9; PubMed PMID: 32532465.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prophylaxis of venous thromboembolism disease in patients with cancer. A1 - Portillo Sánchez,J, Y1 - 2020/06/09/ PY - 2020/02/11/received PY - 2020/04/13/revised PY - 2020/04/18/accepted PY - 2020/6/14/entrez KW - Cancer KW - Cáncer KW - Predicción KW - Prediction KW - Riesgo KW - Risk KW - Thromboprophylaxis KW - Tromboprofilaxis KW - Trombosis venosa KW - Venous thrombosis JF - Revista clinica espanola JO - Rev Clin Esp N2 - Thrombotic risk should always be assessed in the various clinical scenarios of patients with cancer. Thromboprophylaxis with low-molecular-weight heparin is recommended above other anticoagulants for most patients with cancer who are hospitalised. However, the safety of primary thromboprophylaxis in this context is unknown; however, thromboprophylaxis can be completed with mechanical methods. Thromboprophylaxis in outpatients who are treated with chemotherapy is not indicated, except for outpatients who have other factors that determine a high thrombotic risk. In these cases, prophylaxis such as apixaban, rivaroxaban and low-molecular-weight heparin may be employed, provided there are no significant risk factors for bleeding or drug interactions. In patients undergoing oncologic surgery, thromboprophylaxis should be started before the surgery, continuing for at least 7 to 10 days and, in cases of major surgery, even up to 4 weeks. Drug prophylaxis is not routinely recommended to prevent upper extremity thrombosis in patients who carry central venous catheters. SN - 1578-1860 UR - https://www.unboundmedicine.com/medline/citation/32532465/Prophylaxis_of_venous_thromboembolism_disease_in_patients_with_cancer L2 - http://www.elsevier.es/en/linksolver/ft/pii/S0014-2565(20)30133-8 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.